ALK and ROS1 rearrangements, coexistence and treatment in epidermal growth factor receptor-wild type lung adenocarcinoma: a multicenter study of 732 cases.

Song, Zhengbo; Zheng, Yuhui; Wang, Xuzhou; Su, Haiyan; Zhang, Yiping; Song, Yong

Song, Zhengbo; Zheng, Yuhui; Wang, Xuzhou; Su, Haiyan; Zhang, Yiping; Song, Yong.

Afiliación

Song Z; Department of Respiratory Medicine, Jinling Hospital, Nanjing University School of Medicine, Nanjing 210002, China.
Zheng Y; Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou 310022, China.
Wang X; Department of Pathology, Union Hospital, Fujian Medical University, Fuzhou 350001, China.
Su H; Department of Pathology, Fuzhou General Hospital of Nanjing Military Command, Fuzhou 350025, China.
Zhang Y; Department of Pathology, Municipal Hospital of Fujian Province, Zhangzhou 363000, China.
Song Y; Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou 310022, China.

J Thorac Dis ; 9(10): 3919-3926, 2017 Oct.

Article en En | MEDLINE | ID: mdl-29268402

Palabras clave

Lung adenocarcinoma; anaplastic lymphoma kinase (ALK); c-ros oncogene 1 (ROS1); epidermal growth factor receptor (EGFR); frequency, coexistence, efficacy

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Tipo de estudio: Clinical_trials Idioma: En Revista: J Thorac Dis Año: 2017 Tipo del documento: Article País de afiliación: China

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google